KRT88P and nosocomial infection: Although the combination of HBIG and lamivudine or entecavir is often used [11, 12], Chotiyaputta et al. [13] reported that entecavir monotherapy without HBIG is sufficient in preventing HBV cross infection in HBs-Ag negative recipients of HBc-Ab positive donor liver grafts.